Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.51 |
| ▸ | CDK1 | P06493 | 15/20 | 0.51 |
| ▸ | CDK2 | P24941 | 14/20 | 0.51 |
| ▸ | KDR | P35968 | 11/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CDK4 | P11802 | 2/20 | 0.51 |
| ▸ | CDK7 | P50613 | 2/20 | 0.51 |
| ▸ | CDK9 | P50750 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064128 | 1.00 | NTRK1 (0.51) | NTRK1CDK1CDK2KDRCA2 | |
| SCHEMBL4068264 | 0.93 | NTRK1 (0.52) | NTRK1CDK1CDK2KDRCA2 | |
| SCHEMBL4062580 | 0.90 | CDK1 (0.64) | NTRK1CDK1CDK2KDRCA2 | |
| SCHEMBL4061087 | 0.90 | CDK1 (0.54) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4062323 | 0.90 | CDK1 (0.49) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4059716 | 0.89 | NTRK1 (0.43) | NTRK1CDK1CDK2KDRCA2 | |
| SCHEMBL4063398 | 0.88 | CDK1 (0.53) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4064437 | 0.86 | CDK1 (0.55) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4061200 | 0.86 | CDK1 (0.55) | CDK1CDK2KDRCA2CDK4 | |
| SCHEMBL4060305 | 0.85 | CDK1 (0.45) | NTRK1CDK1CDK2KDRCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | SULT2A1, STS, SULT1A1 | NTRK1 3899/4885CDK1 4203/4885CDK2 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.